Literature DB >> 16946878

The future of antidepressant pharmacotherapy.

David Baldwin1, Chris Thompson.   

Abstract

Year:  2003        PMID： 16946878      PMCID： PMC1525061     

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  50 in total

1.  Improving outcomes in depression.

Authors:  M Von Korff; D Goldberg
Journal:  BMJ       Date:  2001-10-27

2.  Clinical psychopharmacology guidelines: different strokes for different folks.

Authors:  Dan J Stein; Yu Xin; David Osser; Xiangyang Li; Kenneth Jobson
Journal:  World J Biol Psychiatry       Date:  2002-04       Impact factor: 4.132

Review 3.  Social functioning in depression: a review.

Authors:  R M Hirschfeld; S A Montgomery; M B Keller; S Kasper; A F Schatzberg; H J Möller; D Healy; D Baldwin; M Humble; M Versiani; R Montenegro; M Bourgeois
Journal:  J Clin Psychiatry       Date:  2000-04       Impact factor: 4.384

Review 4.  Vagus nerve stimulation: a new tool for brain research and therapy.

Authors:  M S George; H A Sackeim; A J Rush; L B Marangell; Z Nahas; M M Husain; S Lisanby; T Burt; J Goldman; J C Ballenger
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

5.  A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression.

Authors:  R M Berman; M Narasimhan; G Sanacora; A P Miano; R E Hoffman; X S Hu; D S Charney; N N Boutros
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

6.  Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Authors:  Guy Griebel; Jacques Simiand; Claudine Serradeil-Le Gal; Jean Wagnon; Marc Pascal; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrie
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

7.  A controlled trial of daily left prefrontal cortex TMS for treating depression.

Authors:  M S George; Z Nahas; M Molloy; A M Speer; N C Oliver; X B Li; G W Arana; S C Risch; J C Ballenger
Journal:  Biol Psychiatry       Date:  2000-11-15       Impact factor: 13.382

8.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Authors:  A W Zobel; T Nickel; H E Künzel; N Ackl; A Sonntag; M Ising; F Holsboer
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

9.  Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

Authors:  Jack M Gorman; Andrew Korotzer; Guojin Su
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790

10.  Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms.

Authors:  J R Redman; B Guardiola-Lemaitre; M Brown; P Delagrange; S M Armstrong
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.